COMPARING FIRST- AND SECOND-SEASON PALIVIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMODYNAMICALLY SIGNIFICANT CONGENITAL HEART DISEASE IN THE CARESS DATABASE (2005-2014)
Author(s)
Li A1, Paes B2, Mitchell I3, Lanctôt K1
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3University of Calgary, Calgary, AB, Canada
OBJECTIVES: Paediatric advisory guidelines recommend prophylaxis against respiratory syncytial virus (RSV) for infants with hemodynamically significant congenital heart disease (HSCHD). However, current recommendations have cast doubt as to whether prophylaxis is beneficial after 1year of age. The objective of this study is to determine whether there are differences in RSV-related hospitalizations (RSVH) in HSCHD infants receiving palivizumab during the first versus second season in the Canadian Registry of palivizumab (CARESS) database METHODS: CARESS is a prospective registry of infants who have received ≥1 dose of palivizumab at one of 32 sites across Canada during the 2005-2014 RSV seasons. Demographic data were collected at enrollment and respiratory-illness-related hospitalization events were recorded monthly. Only infants aged <24 months with HSCHD were included in the analysis. RESULTS:
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PIN29
Topic
Epidemiology & Public Health
Disease
Infectious Disease (non-vaccine)